Association Between Circulating BDNF Levels and Cardioembolic Strokes in Patients Treated for Ischemic Stroke

NCT07624396 | Not Yet Recruiting

• 1 other identifier: GUENANCIA ANR 2024
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

Atrial fibrillation (AF) is associated with serious complications, including embolic strokes, heart failure, and mortality. Disruption of normal blood flow in the atrium, particularly in the context of an endocardium predisposed to thrombosis, increases the risk of thrombus formation. Once dislodged from the atrial cavity and traveling to the cerebral arteries, these thrombi can cause a cardioembolic stroke. The main risk factors for atrial cardiomyopathy (ACM) and AF are metabolic syndrome and aging. ACM is a condition that is difficult to diagnose because it is not clearly defined, except through histological analysis. Guided by the results of our experimental approaches, the investigators aim to address this challenge by examining ACM through the lens of one of its complications: cardioembolic stroke. BDNF (Brain-Derived Neurotrophic Factor) is a neurotrophic factor involved in inflammatory and metabolic processes that may play a key role in the development of these complications. This study explores the association between circulating levels of BDNF and the morphological and metabolic characteristics of ACM, as assessed by cardiac and brain imaging studies

Conditions

Acute Ischemic Stroke

Outcome Measures

Primary Outcomes (1)

• Diagnosis of cardioembolic stroke according to the TOAST classification, adjudicated with a blinded review of biomarker data by the treating of a neurologist upon the patient' s hospital discharge.

  At hospital discharge (approximately 5 to 10 day after admission)

Study Arms (1)

Patient who has suffered an acute ischemic stroke

Patient diagnosed with acute ischemic stroke based on brain imaging

Biological: Circulating BDNF levels measured via blood sample

Interventions

Circulating BDNF levels measured via blood sample BIOLOGICAL

Diagnosis of cardioembolic stroke according to the TOAST13 classification, adjudicated with a blinded review of biomarker data by the treating of a neurologist upon the patient' s hospital discharge

Patient who has suffered an acute ischemic stroke

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

A patient diagnosed with acute ischemic stroke, confirmed by brain imaging (CT or MRI).

You may qualify if:

• Individuals who provided informed consent
• Diagnosis of acute ischemic stroke confirmed by brain imaging (CT or MRI)
• Underwent a combined cardiac and brain CT scan within 24 hours of admission for stroke

You may not qualify if:

• A person subject to a legal protective measure (guardianship, conservatorship)
• A person subject to a judicial safeguard measure
• A pregnant woman, a woman who has recently given birth, or a breastfeeding woman
• An adult who is legally incapacitated or unable to give consent,
• A minor

Sponsors & Collaborators

• Centre Hospitalier Universitaire Dijon: lead

Study Sites (1)

Chu Dijon Bourgogne

Dijon, France

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood samples will be collected and processed to obtain serum. Serum sample will be aliquoted and stored for analysis of circulating protein biomarkers, including BDNF, osteoprotegerin, galectin-3, BMP-10, and PR pro-ANP. No genetic analyses will be performed.

MeSH Terms

Conditions

Ischemic Stroke

Condition Hierarchy (Ancestors)

Stroke; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases

Central Study Contacts

Charles GUENANCIA, Pr

CONTACT

03.80.29.56.23; charles.guenancia@chu-dijon.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 36 Months
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 17, 2026
• First Posted: June 3, 2026
• Study Start: June 1, 2026
• Primary Completion (Estimated): June 1, 2031
• Study Completion (Estimated): June 1, 2031
• Last Updated: June 3, 2026

Record last verified: 2026-06

Locations

FR (1)